Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Nicole Bowan

Physician Assistant, Medical Wexford, PA Physician Assistant

NPI 1295731693 CMS profile 10824483

5500 Brooktree Rd, Ste 201, Wexford, PA 15090

Open in the dashboard

General payments

$3,821

159 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nicole Bowan of Wexford, PA is reported in the CMS Open Payments database as having received $3,821 across 159 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,240 48
2024 General $1,424 58
2023 General $858 40
2022 General $146 7
2021 General $153 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nicole Bowan
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Nicole Bowan were reported at $1,240. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Nicole Bowan Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $153 $156 $41–$563 $132
2022 $146 $185 $55–$649 $149
2023 $858 $199 $58–$717 $160
2024 $1,424 $206 $62–$740 $164
2025 $1,240 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $730 28 payments
  2. AbbVie, Inc. $494 26 payments
  3. Phathom Pharmaceuticals, Inc. $350 13 payments
  4. Regeneron Healthcare Solutions, Inc. $348 13 payments
  5. Janssen Scientific Affairs, LLC $303 3 payments
  6. Genzyme Corporation $296 15 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $251 12 payments
  8. Ardelyx, Inc. $207 11 payments
  9. Braintree Laboratories, Inc. $114 6 payments
  10. Daiichi Sankyo Inc. $111 5 payments
  11. Other $617 27 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,807 158 payments
  2. Education $14 1 payment
Products named General payments · program years 2021–2025
  1. TREMFYA $754 20 payments
  2. STELARA $372 16 payments
  3. DUPIXENT Inflammation And Immunology $320 12 payments
  4. DUPIXENT Immunology $296 15 payments
  5. VOQUEZNA $250 7 payments
  6. LINZESS $234 10 payments
  7. IBSRELA $207 11 payments
  8. RINVOQ $197 13 payments
  9. CREON $180 6 payments
  10. EOHILIA $128 6 payments
  11. Other $1,636 83 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

3,370

Median for Physician Assistant: 241

Drug cost

$231,552

Median for Physician Assistant: $4,110

Branded share of claims

31.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 99 $63,199
Mesalamine Generic 76 $45,749
Pentasa Mesalamine Brand 13 $19,374
Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg Brand 616 $12,470
Rabeprazole Sodium Generic 397 $10,818
Lubiprostone Generic 63 $10,671
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 68 $10,614
Mesalamine Er Mesalamine Brand 16 $9,995
Budesonide Dr Budesonide Brand 52 $9,580
Colestipol Hcl Generic 91 $6,518

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$14,592

Medicare's payments for the services billed

Medicare patients

182

Average age 73

Services billed

274

103 women, 79 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 57%
Ischemic heart disease 35%
Diabetes 30%
Chronic kidney disease 28%
Depression 25%
COPD 21%
Atrial fibrillation 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $189
  • GENZYME CORPORATION $160
$350 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $221
$221 — —
TREMFYA
  • Janssen Scientific Affairs, LLC $110
  • Janssen Biotech, Inc. $59
$169 — —
LINZESS
  • Ironwood Pharmaceuticals, Inc $73
  • AbbVie, Inc. $23
$96 99 —
STELARA
  • Janssen Biotech, Inc. $96
$96 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

159 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record